Clinical outcomes of dry-preserved amniotic membrane allograft transplant for ocular surface disease

Clinical outcomes of dry-preserved amniotic membrane allograft transplant for ocular surface disease - DAMAT for OSD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044150

Enrollment

Registered

2021-05-09

Start date

2018-04-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular suface disease

Interventions

single application of dry-preserved amniotic membrane retained by soft contact lenses, Dry-preserved membrane applied once and removed after 2 to 3 week interval

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. ocular surface disease 2. Persistent corneal epithelial defect 3. Thermal/Chemical Burn 4, Corneal ulcer/scar 5, Dry Eye Syndrome 6. Dysfunctional Tear Syndrome 7. Filamentary keratitis

Exclusion criteria

Exclusion criteria: Subjects were excluded from the study if any of the following criteria was fulfilled, corneal or scleral perforation or impending perforation, subjects with recent or active infection, subjects not able to understand the character and individual consequences of the investigation, and participation in other clinical research within the last 8 weeks.

Design outcomes

Primary

Measure	Time frame
1) Rate of retention of dehydrated amniotic membrane/ soft contact lens 2) Pain/Photophobia scale 3) Visual Acuity (BSCVA) 4) External Eye Examination 5) Slit-lamp Examination	—

Secondary

Measure	Time frame
Adverse events	—

Countries

Asia(except Japan)

Contacts

Public ContactAngeline Chiong

Peregrine Eye and Laser Institute Research Section

angeline.chiong@peregrineeye.com63288900115

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026